Aptus Pharma Ltd
Aptus Pharma Ltd (APPL) last traded at ₹302, a market capitalisation of ₹518 crore, on a P/E of 112. Over the past 52 weeks the stock has ranged between ₹32.3 and ₹310. Aptus Pharma Ltd last reported results for the quarter ended Mar 2026, with sales of ₹32.2 crore and net profit of ₹2.87 crore. The next scheduled event is a preferential issue on 14 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Aptus Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Aptus Pharma Ltd quarterly results
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 9.76 | 14.8 | 14.38 | 32.2 |
| Expenses | 7.78 | 11.93 | 11.45 | 27.7 |
| Operating profit | 1.98 | 2.87 | 2.93 | 4.5 |
| OPM % | 20.29% | 19.39% | 20.38% | 13.98% |
| Other income | 0 | 0.08 | 0.01 | 0.12 |
| Interest | 0.11 | 0.36 | 0.43 | 0.35 |
| Depreciation | 0.11 | 0.15 | 0.16 | 0.25 |
| Profit before tax | 1.76 | 2.44 | 2.35 | 4.02 |
| Tax % | 25.57% | 26.23% | 25.53% | 28.61% |
| Net profit | 1.31 | 1.79 | 1.75 | 2.87 |
| EPS (₹) | 5.24 | 1.43 | 1.02 | 1.67 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aptus Pharma Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 13.9 | 17.81 | 24.56 | 46.57 |
| Operating profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16.00% |
| Net profit | 0.19 | 0.8 | 3.1 | 4.62 |
| EPS (₹) | 2.38 | 10.00 | 2.48 | 2.69 |
TTM is the trailing twelve months to the most recent quarter.
Aptus Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 50%
- TTM
- 90%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 190%
- TTM
- 49%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 41%
- Last Year
- 30%
Aptus Pharma Ltd shareholding pattern
Promoters held 72.89% at Jun 2026, broadly unchanged since Sep 2025. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 72.89% | 72.89% | 72.89% | 72.89% |
| FIIs | 10.03% | 0.00% | 0.00% | 0.00% |
| DIIs | 2.80% | 0.00% | 0.00% | 0.00% |
| Public | 14.29% | 27.11% | 27.11% | 27.11% |
| No. of shareholders | 213 | 302 | 337 | 686 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Aptus Pharma Ltd events
The next scheduled event is a preferential issue on 14 Sept 2026.
- Preferential issuePreferential allotment of 16,10,100 equity shares to 192 investors
- AGMAnnual General Meeting including approval of preferential allotment of equity shares
See the full results calendar for every Indian company reporting in the next 30 days.
Aptus Pharma Ltd corporate filings
- Aptus Pharma Limited - Press release regarding - Aptus Pharma Limited charts next growth phase with focus on manufacturing, pan-India expansion and global marketsCompany Updatelow impact
Cruxal's analysis: Aptus Pharma has released a strategic update outlining its next growth phase, which…
Read the full analysis - Intimation of investor presentation under regulation 30 of SEBI (LODR) Regulations, 2015Company Updatehigh impact
Cruxal's analysis: Aptus Pharma Limited has released its investor presentation for the financial year ended…
Read the full analysis - SUB: Submission of Annual Report for the FY 2025-26 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial StatementsOthershigh impact
Cruxal's analysis: Aptus Pharma Limited has released its FY 2025-26 Annual Report, highlighting strong…
Read the full analysis - Notice is hereby given that the Annual General Meeting of the Company will be held on Monday 14th September, 2026, Through Video Conferencing (VC)/ Other Audio visual means.AGM/EGMhigh impact
Cruxal's analysis: Aptus Pharma Limited has announced a preferential allotment of 16,02,870 equity shares at…
Read the full analysis - Outcome of Board Meeting dated 17.08.2026Board Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has announced the approval of a preferential issue of 16.03 lakh…
Read the full analysis - Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve Prior Intimation of Board Meeting ....Board Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has scheduled a Board Meeting for August 17, 2026, to deliberate on…
Read the full analysis - Clarification Letter In Respect Of Outcome Of Board Meeting Held On 08.08.2026Company Updatelow impact
Cruxal's analysis: Aptus Pharma Limited has issued a formal clarification to the BSE regarding minor…
Read the full analysis - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Preferential Issue Of SharesBoard Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has announced a board-approved preferential issue of 16,10,100…
Read the full analysis - Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....Board Meetingmedium impact
Cruxal's analysis: Aptus Pharma Limited has scheduled a board meeting for August 8, 2026, to evaluate a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Aptus Pharma Ltd
Cruxal reads every Aptus Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.